When it comes to treatment for gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, one option is radioligand therapy. While outcomes may vary, it can be a highly effective treatment for these tumors that form in the gastrointestinal tract.
“Radioligand therapy is kind of unparalleled when compared to other treatments that are available,” says Kimberly Perez, MD, Medical Oncologist at the Dana-Farber Cancer Institute in Boston.
Is radioligand therapy right for you?
Radioligand therapy is given by an infusion that targets receptors on the tumor cells called somatostatin receptors. If your GEP-NETs have a lot of somatostatin receptors, radioligand therapy might work well for you.
In order to determine this, your care team will do an imaging test called a PET dotatate scan.
“That scan allows us to determine how much of the receptor is on the tumor cells and in all the sites that the disease is present,” says Perez. If your tumor cells do not have enough of these receptors, radioligand therapy may not be right for you.
Another factor is whether your cancer is stable or progressing. If it turns out that your tumor is stable, this means that it isn’t growing. This means you may not need radioligand therapy.
Is radioligand therapy safe for people who are pregnant or breastfeeding?
There hasn’t been any research done on whether radioligand therapy is effective if you’re pregnant or breastfeeding. If you are, you may not be a good candidate for radioligand therapy.
What are tips to talk to your care team about GEP-NET treatments?
Before you receive radioligand therapy, here are a few tips from Perez about how to get the most out of your treatment:
Write down your questions for your care team beforehand
Send messages to your doctor before the visit
Bring a loved one with you to your appointment
“I think the most important part of the care team relationship is that they’re aware of what your needs and questions are,” she adds.
Kimberly Perez, MD, is a Medical Oncologist at the Dana Farber Cancer Institute in Boston, MA.
References
Chan, J. A., et al. (2023). Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion. UpToDate.
Cives, M., et al. (2018). Gastroenteropancreatic neuroendocrine tumors. CA: A Cancer Journal for Clinicians.
Guide to Pharmacology. (n.d.). Somatostatin receptors: Introduction.
U.S. Food & Drug Administration. (2018). FDA approves new treatment for certain digestive tract cancers.
U.S. Food & Drug Administration. (2022). LUTATHERA [package insert].
Why trust our experts?











